Tegoprazan (CJ-12420, IN-A001, K-CAB, LXI-15028) is a potassium-competitive acid blocker and a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan (3 μM) inhibits 86% of H+/K+-ATPase activity, whereas the inhibition is decreased to 34% after the dilution of Tegoprazan concentration to 0.15 μM.
In vivo, Tegoprazan (1.0 mg/kg, p.o.) potently and completely inhibits histamine-induced gastric acid secretion in dogs. Tegoprazan (1.0-3.0 mg/kg, p.o.) reverses the pentagastrin-induced acidified gastric pH to the neutral range.
|Solubility (25°C)||DMSO ≥ 60 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related ATPase Products|
Prilocaine acetate, an amino amide, is a Na/K-ATPase inhibitor.
Chamigrenol is a Na+/K+-ATPase inhibitor with an IC50 value of 15.9 μg/mL.
ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function.
|ATP synthase inhibitor 2 TFA
ATP synthase inhibitor 2 TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL).
Apicularen B is a cytotoxic macrolide produced by Archangium gephyra and is also a specific V-ATPase inhibitor. Its IC50 values range from 0.2 to 1.2 μg/mL and it exhibits weak activity against some Gram-positive bacteria.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.